An Exercise Intervention During Chemotherapy for Women With Recurrent Ovarian Cancer A Feasibility Study

被引:44
|
作者
Mizrahi, David [1 ,2 ]
Broderick, Carolyn [1 ]
Friedlander, Michael [1 ,3 ]
Ryan, Mary [3 ]
Harrison, Michelle [4 ]
Pumpa, Kate [5 ]
Naumann, Fiona [6 ]
机构
[1] Univ New S Wales, Sch Med Sci, Sydney, NSW, Australia
[2] Sydney Childrens Hosp, Kids Canc Ctr, Sydney, NSW, Australia
[3] Royal Hosp Women, Gynaecol Oncol, Sydney, NSW, Australia
[4] Prince Alfred Hosp, Royal Sydney Canc Ctr, Sydney, NSW, Australia
[5] Univ Canberra, Res Inst Sport & Exercise, Canberra, ACT 2601, Australia
[6] Queensland Univ Technol, Sch Exercise & Nutr Sci, Brisbane, Qld 4001, Australia
关键词
Cancer; Oncology; Exercise; Physical activity; Chemotherapy; Quality of life; QUALITY-OF-LIFE; PHYSICAL-ACTIVITY; VALIDATION; FATIGUE; THERAPY; RESISTANCE; SYMPTOMS; SAFETY;
D O I
10.1097/IGC.0000000000000460
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective The aim of this study was to determine the feasibility of a combined supervised and home-based exercise intervention during chemotherapy for women with recurrent ovarian cancer. Secondary aims were to determine the impact of physical activity on physical and psychological outcomes and on chemotherapy completion rates. Methods Women with recurrent ovarian cancer were recruited from 3 oncology outpatient clinics in Sydney and Canberra, Australia. All participants received an individualized exercise program that consisted of 90 minutes or more of low to moderate aerobic, resistance, core stability, and balance exercise per week, for 12 weeks. Feasibility was determined by recruitment rate, retention rate, intervention adherence, and adverse events. Aerobic capacity, muscular strength, fatigue, sleep quality, quality of life, depression, and chemotherapy completion rates were assessed at weeks 0, 12, and 24. Results Thirty participants were recruited (recruitment rate, 63%), with a retention rate of 70%. Participants averaged 196 138 min.wk of low to moderate physical activity throughout the intervention, with adherence to the program at 81%. There were no adverse events resulting from the exercise intervention. Participants who completed the study displayed significant improvements in quality of life (P = 0.017), fatigue (P = 0.004), mental health (P = 0.007), muscular strength (P = 0.001), and balance (P = 0.003) after the intervention. Participants completing the intervention had a higher relative dose intensity than noncompleters (P = 0.03). Conclusions A program consisting of low to moderate exercise of 90 min.wk was achieved by two-thirds of women with recurrent ovarian cancer in this study, with no adverse events reported. Randomized control studies are required to confirm the benefits of exercise reported in this study.
引用
收藏
页码:985 / 992
页数:8
相关论文
共 50 条
  • [1] FEASIBILITY OF A BRIEF YOGA INTERVENTION DURING CHEMOTHERAPY FOR PERSISTENT OR RECURRENT OVARIAN CANCER
    Sohl, Stephanie J.
    Danhauer, Suzanne C.
    Schnur, Julie B.
    Daly, Leslie
    Suslov, Kathryn
    Montgomery, Guy H.
    EXPLORE-THE JOURNAL OF SCIENCE AND HEALING, 2012, 8 (03) : 197 - 198
  • [2] Exercise during chemotherapy for recurrent ovarian cancer (ECHO-R): A Phase II trial evaluating feasibility, safety and efficacy of an individually-tailored exercise intervention during chemotherapy for recurrent ovarian cancer
    Sandler, Carolina
    Spence, Rosalind
    Obermair, Andreas
    Janda, Monika
    Eakin, Elizabeth
    Beesley, Vanessa
    Vegenas, Domitrios
    Gordon, Louisa
    Webb, Penelope
    Williams, Merran
    O'Neill, Helene
    Hayes, Sandi
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 229 - 230
  • [3] The role of exercise intervention in women with ovarian cancer undergoing chemotherapy: a systematic review
    Rusbiyanto, M. C.
    Sabran, M. Z.
    Sutanto, R.
    Sukendro, G. M.
    Kurniawan, A.
    Huang, I.
    ANNALS OF ONCOLOGY, 2024, 35 : S1335 - S1335
  • [4] Safety, feasibility and effects of an individualised walking intervention for women undergoing chemotherapy for ovarian cancer: a pilot study
    Melissa J Newton
    Sandi C Hayes
    Monika Janda
    Penelope M Webb
    Andreas Obermair
    Elizabeth G Eakin
    David Wyld
    Louisa G Gordon
    Vanessa L Beesley
    BMC Cancer, 11
  • [5] Safety, feasibility and effects of an individualised walking intervention for women undergoing chemotherapy for ovarian cancer: a pilot study
    Newton, Melissa J.
    Hayes, Sandi C.
    Janda, Monika
    Webb, Penelope M.
    Obermair, Andreas
    Eakin, Elizabeth G.
    Wyld, David
    Gordon, Louisa G.
    Beesley, Vanessa L.
    BMC CANCER, 2011, 11
  • [6] Pre-post feasibility trial of a telephone-delivered exercise intervention for patients during chemotherapy for recurrent ovarian cancer: the ECHO-R trial protocol
    Hayes, Sandra C.
    Spence, Rosalind R.
    Janda, Monika
    Eakin, Elizabeth
    Shannon, Catherine
    Goh, Jeffrey
    Beesley, Vanessa L.
    Vagenas, Dimitrios
    Webb, Penny
    Coward, Jermaine
    Gordon, Louisa G.
    O'Neill, Helene
    Williams, Merran
    Rye, Sheree
    Newton, Melissa J.
    Baniahmadi, Sara
    Nascimento, Marcelo
    Nicklin, James
    Garret, Andrea
    Obermair, Andreas
    BMJ OPEN, 2024, 14 (01):
  • [7] Centering Prayer for Women Receiving Chemotherapy for Recurrent Ovarian Cancer: A Pilot Study
    Johnson, Mary E.
    Dose, Ann M.
    Pipe, Teri Britt
    Petersen, Wesley O.
    Huschka, Mashele
    Gallenberg, Mary M.
    Peethambaram, Prema
    Sloan, Jeff
    Frost, Marlene H.
    ONCOLOGY NURSING FORUM, 2009, 36 (04) : 421 - 428
  • [8] A pilot study of exercise intervention during chemotherapy in patients with metastatic cancer
    Ahn, H. K.
    Kim, Y. S.
    Kim, E. Y.
    Park, K. D.
    Park, I.
    Sym, S. J.
    Park, S. H.
    Shin, D. B.
    ANNALS OF ONCOLOGY, 2018, 29
  • [9] Randomised controlled trial testing the feasibility of an exercise and nutrition intervention for patients with ovarian cancer during and after first-line chemotherapy (BENITA-study)
    Maurer, Tabea
    Belau, Matthias Hans
    von Grundherr, Julia
    Schlemmer, Zoe
    Patra, Stefan
    Becher, Heiko
    Schulz, Karl-Heinz
    Zyriax, Birgit-Christiane
    Schmalfeldt, Barbara
    Chang-Claude, Jenny
    BMJ OPEN, 2022, 12 (02):
  • [10] A FEASIBILITY STUDY OF GEMCITABINE AND BEVACIZUMAB IN WOMEN WITH PLATINUM-RESISTANT RECURRENT OVARIAN CANCER
    Nagao, S.
    Kogiku, A.
    Ota, M.
    Yamamoto, K.
    Narita, M.
    Shimada, K.
    Nagazawa, H.
    Shibutani, T.
    Yamamoto, K.
    Jimi, T.
    Yano, H.
    Kitai, M.
    Shiozaki, T.
    Matsuoka, K.
    Yamaguchi, S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A501 - A501